Selected research
Industry Research
Candidiasis Therapeutics Industry Research Report 2026
Market perspective
The global Candidiasis Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Candidiasis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Candidiasis Therapeutics is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Candidiasis Therapeutics is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Candidiasis Therapeutics include Novartis AG, F. Hoffmann-La Roche Ltd., Bayer-Algeta, Amgen, Merrion Pharmaceuticals Plc., Medivir AB, Genta Incorporated, Galapagos NV and Digna Biotech S.L., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Candidiasis Therapeutics market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Candidiasis Therapeutics Market by Company
Novartis AG
F. Hoffmann-La Roche Ltd.
Bayer-Algeta
Amgen
Merrion Pharmaceuticals Plc.
Medivir AB
Genta Incorporated
Galapagos NV
Digna Biotech S.L.
Catena Pharmaceuticals Inc.
Amura Holdings
Ablynx
Candidiasis Therapeutics Segment by Type
Vincristine
Ifosfamide
Etoposide
Cisplatin
Methotrexate
Cyclophosphamide
Doxorubicin
7Carboplatin
Candidiasis Therapeutics Segment by Application
Multispecialty Hospitals
Cancer Research Institutes
Others
Candidiasis Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Candidiasis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Candidiasis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Candidiasis Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Candidiasis Therapeutics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Candidiasis Therapeutics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Candidiasis Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Vincristine
- Ifosfamide
- Etoposide
- Cisplatin
- Methotrexate
- Cyclophosphamide
- Doxorubicin
- 7Carboplatin
Applications
- Multispecialty Hospitals
- Cancer Research Institutes
- Others
Companies covered
- Novartis AG
- F. Hoffmann-La Roche Ltd.
- Bayer-Algeta
- Amgen
- Merrion Pharmaceuticals Plc.
- Medivir AB
- Genta Incorporated
- Galapagos NV
- Digna Biotech S.L.
- Catena Pharmaceuticals Inc.
- Amura Holdings
- Ablynx
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Candidiasis Therapeutics Market Size (2021-2032)
- 2.2.2 Global Candidiasis Therapeutics Sales (2021-2032)
- 2.2.3 Global Candidiasis Therapeutics Market Average Price (2021-2032)
- 2.3 Candidiasis Therapeutics by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Vincristine
- 2.3.3 Ifosfamide
- 2.3.4 Etoposide
- 2.3.5 Cisplatin
- 2.3.6 Methotrexate
- 2.3.7 Cyclophosphamide
- 2.3.8 Doxorubicin
- 2.3.9 7Carboplatin
- 2.4 Candidiasis Therapeutics by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Multispecialty Hospitals
- 2.4.3 Cancer Research Institutes
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Candidiasis Therapeutics Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Candidiasis Therapeutics Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Candidiasis Therapeutics Revenue of Manufacturers (2021-2026)
- 3.4 Global Candidiasis Therapeutics Average Price by Manufacturers (2021-2026)
- 3.5 Global Candidiasis Therapeutics Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Candidiasis Therapeutics, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Candidiasis Therapeutics, Product Type & Application
- 3.8 Global Manufacturers of Candidiasis Therapeutics, Established Date
- 3.9 Global Candidiasis Therapeutics Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis AG
- 4.1.1 Novartis AG Company Information
- 4.1.2 Novartis AG Business Overview
- 4.1.3 Novartis AG Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis AG Candidiasis Therapeutics Product Portfolio
- 4.1.5 Novartis AG Recent Developments
- 4.2 F. Hoffmann-La Roche Ltd.
- 4.2.1 F. Hoffmann-La Roche Ltd. Company Information
- 4.2.2 F. Hoffmann-La Roche Ltd. Business Overview
- 4.2.3 F. Hoffmann-La Roche Ltd. Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 F. Hoffmann-La Roche Ltd. Candidiasis Therapeutics Product Portfolio
- 4.2.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 4.3 Bayer-Algeta
- 4.3.1 Bayer-Algeta Company Information
- 4.3.2 Bayer-Algeta Business Overview
- 4.3.3 Bayer-Algeta Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bayer-Algeta Candidiasis Therapeutics Product Portfolio
- 4.3.5 Bayer-Algeta Recent Developments
- 4.4 Amgen
- 4.4.1 Amgen Company Information
- 4.4.2 Amgen Business Overview
- 4.4.3 Amgen Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Amgen Candidiasis Therapeutics Product Portfolio
- 4.4.5 Amgen Recent Developments
- 4.5 Merrion Pharmaceuticals Plc.
- 4.5.1 Merrion Pharmaceuticals Plc. Company Information
- 4.5.2 Merrion Pharmaceuticals Plc. Business Overview
- 4.5.3 Merrion Pharmaceuticals Plc. Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merrion Pharmaceuticals Plc. Candidiasis Therapeutics Product Portfolio
- 4.5.5 Merrion Pharmaceuticals Plc. Recent Developments
- 4.6 Medivir AB
- 4.6.1 Medivir AB Company Information
- 4.6.2 Medivir AB Business Overview
- 4.6.3 Medivir AB Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Medivir AB Candidiasis Therapeutics Product Portfolio
- 4.6.5 Medivir AB Recent Developments
- 4.7 Genta Incorporated
- 4.7.1 Genta Incorporated Company Information
- 4.7.2 Genta Incorporated Business Overview
- 4.7.3 Genta Incorporated Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Genta Incorporated Candidiasis Therapeutics Product Portfolio
- 4.7.5 Genta Incorporated Recent Developments
- 4.8 Galapagos NV
- 4.8.1 Galapagos NV Company Information
- 4.8.2 Galapagos NV Business Overview
- 4.8.3 Galapagos NV Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Galapagos NV Candidiasis Therapeutics Product Portfolio
- 4.8.5 Galapagos NV Recent Developments
- 4.9 Digna Biotech S.L.
- 4.9.1 Digna Biotech S.L. Company Information
- 4.9.2 Digna Biotech S.L. Business Overview
- 4.9.3 Digna Biotech S.L. Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Digna Biotech S.L. Candidiasis Therapeutics Product Portfolio
- 4.9.5 Digna Biotech S.L. Recent Developments
- 4.10 Catena Pharmaceuticals Inc.
- 4.10.1 Catena Pharmaceuticals Inc. Company Information
- 4.10.2 Catena Pharmaceuticals Inc. Business Overview
- 4.10.3 Catena Pharmaceuticals Inc. Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Catena Pharmaceuticals Inc. Candidiasis Therapeutics Product Portfolio
- 4.10.5 Catena Pharmaceuticals Inc. Recent Developments
- 4.11 Amura Holdings
- 4.11.1 Amura Holdings Company Information
- 4.11.2 Amura Holdings Business Overview
- 4.11.3 Amura Holdings Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Amura Holdings Candidiasis Therapeutics Product Portfolio
- 4.11.5 Amura Holdings Recent Developments
- 4.12 Ablynx
- 4.12.1 Ablynx Company Information
- 4.12.2 Ablynx Business Overview
- 4.12.3 Ablynx Candidiasis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Ablynx Candidiasis Therapeutics Product Portfolio
- 4.12.5 Ablynx Recent Developments
5 Global Candidiasis Therapeutics Market Scenario by Region
- 5.1 Global Candidiasis Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Candidiasis Therapeutics Sales by Region: 2021-2032
- 5.2.1 Global Candidiasis Therapeutics Sales by Region: 2021-2026
- 5.2.2 Global Candidiasis Therapeutics Sales by Region: 2027-2032
- 5.3 Global Candidiasis Therapeutics Revenue by Region: 2021-2032
- 5.3.1 Global Candidiasis Therapeutics Revenue by Region: 2021-2026
- 5.3.2 Global Candidiasis Therapeutics Revenue by Region: 2027-2032
- 5.4 North America Candidiasis Therapeutics Market Facts & Figures by Country
- 5.4.1 North America Candidiasis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Candidiasis Therapeutics Sales by Country (2021-2032)
- 5.4.3 North America Candidiasis Therapeutics Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Candidiasis Therapeutics Market Facts & Figures by Country
- 5.5.1 Europe Candidiasis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Candidiasis Therapeutics Sales by Country (2021-2032)
- 5.5.3 Europe Candidiasis Therapeutics Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Candidiasis Therapeutics Market Facts & Figures by Country
- 5.6.1 Asia Pacific Candidiasis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Candidiasis Therapeutics Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Candidiasis Therapeutics Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Candidiasis Therapeutics Market Facts & Figures by Country
- 5.7.1 South America Candidiasis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Candidiasis Therapeutics Sales by Country (2021-2032)
- 5.7.3 South America Candidiasis Therapeutics Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Candidiasis Therapeutics Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Candidiasis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Candidiasis Therapeutics Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Candidiasis Therapeutics Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Candidiasis Therapeutics Sales by Type (2021-2032)
- 6.1.1 Global Candidiasis Therapeutics Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Candidiasis Therapeutics Sales Market Share by Type (2021-2032)
- 6.2 Global Candidiasis Therapeutics Revenue by Type (2021-2032)
- 6.2.1 Global Candidiasis Therapeutics Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Candidiasis Therapeutics Revenue Market Share by Type (2021-2032)
- 6.3 Global Candidiasis Therapeutics Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Candidiasis Therapeutics Sales by Application (2021-2032)
- 7.1.1 Global Candidiasis Therapeutics Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Candidiasis Therapeutics Sales Market Share by Application (2021-2032)
- 7.2 Global Candidiasis Therapeutics Revenue by Application (2021-2032)
- 7.2.1 Global Candidiasis Therapeutics Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Candidiasis Therapeutics Revenue Market Share by Application (2021-2032)
- 7.3 Global Candidiasis Therapeutics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Candidiasis Therapeutics Value Chain Analysis
- 8.1.1 Candidiasis Therapeutics Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Candidiasis Therapeutics Production Mode & Process
- 8.2 Candidiasis Therapeutics Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Candidiasis Therapeutics Distributors
- 8.2.3 Candidiasis Therapeutics Customers
9 Global Candidiasis Therapeutics Analyzing Market Dynamics
- 9.1 Candidiasis Therapeutics Industry Trends
- 9.2 Candidiasis Therapeutics Industry Drivers
- 9.3 Candidiasis Therapeutics Industry Opportunities and Challenges
- 9.4 Candidiasis Therapeutics Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst